

IN THE SPECIFICATION

Page 17, second paragraph, lines 7-12, please amend the Specification as follows:

Rational design of novel RANKL variants may be achieved by using, for example, Protein Design Automation[®] (PDA[®]) technology. (See U.S. Patent Nos. 6,188,965; 6,269,312; 6,403,312; 6,188,965; 6,269,312; 6,403,312; 6,177,318; 7,315,786; WO98/47089 and USSNs 09/058,459, 09/127,926, 60/104,612, 60/158,700, 09/419,354, 60/181,630, 60/186,904, 09/419,564, 09/782,004 and 09/927,790, 60/347,772, and 10/218,102; and PCT/US01/218,102 and U.S.S.N. 40/218,102, U.S.S.N. 60/345,805; U.S.S.N. 60/373,453 and U.S.S.N. 60/374,035, all references expressly incorporated herein in their entirety.)